ABERA TESFAYE: Open Payments
NPI 1396339727 · CHULA VISTA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,209 in 52 payments from 8 companies in 2025. Trend: 2023 $1,092 · 2024 $772 · 2025 $1,209
Food & beverage: $1,203Education: $7
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $376 |
| Neurocrine BioSciences, Inc. | 3 | $173 |
| Alkermes, Inc. | 10 | $168 |
| E.R. Squibb & Sons, L.L.C. | 14 | $164 |
| Otsuka America Pharmaceutical, Inc. | 6 | $157 |
| Teva Pharmaceuticals USA, Inc. | 4 | $73 |
| Janssen Pharmaceuticals, Inc | 3 | $62 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
Products named: CAPLYTA, INGREZZA, COBENFY, ARISTADA, REXULTI, INVEGA SUSTENNA, ABILIFY ASIMTUFII, UZEDY.
Industry payments across CA — which companies pay providers there.
